source
- Obesity drug market surges as Lilly, Novo Nordisk lead and rivals chase $200B opportunityEli Lilly and Novo Nordisk continue to dominate the early market for obesity treatments, expanding their prescription bases with new oral products. Meanwhile, a range of larger and smaller compani…
- Gilead secures another FDA approval for HIV therapy, bolstering lenacapavir portfolioGilead Sciences announced that the U.S. Food and Drug Administration has approved a new HIV treatment, adding to the company's growing portfolio of antiviral drugs. The approval extends the reach o…